Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francien Talens

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cell Cycle (Georgetown, Tex.)|July 2, 2019
Inflammatory signaling in genomically instable cancersFrancien Talens, Marcel A T M Van Vugt
Expert Opinion on Drug Discovery|April 21, 2017
Therapeutic targeting and patient selection for cancers with homologous recombination defectsFrancien Talens, Mathilde Jalving, Jourik A Gietema, et al.
Nature Communications|January 11, 2019
BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicityAnne Margriet Heijink, Francien Talens, Lucas T Jae, et al.
Nature Communications|July 18, 2017
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cellsPepijn M Schoonen, Francien Talens, Colin Stok, et al.
NAR Cancer|November 29, 2024
RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft modelsFrancien Talens, Vivian Oliviera Nunes Teixeira, Yannick P Kok, et al.
Nature Communications|November 3, 2022
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signalingDario Zimmerli, Chiara S Brambillasca, Francien Talens, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cell Cycle (Georgetown, Tex.)|July 2, 2019
Inflammatory signaling in genomically instable cancersFrancien Talens, Marcel A T M Van Vugt
Expert Opinion on Drug Discovery|April 21, 2017
Therapeutic targeting and patient selection for cancers with homologous recombination defectsFrancien Talens, Mathilde Jalving, Jourik A Gietema, et al.
Nature Communications|January 11, 2019
BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicityAnne Margriet Heijink, Francien Talens, Lucas T Jae, et al.
Nature Communications|July 18, 2017
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cellsPepijn M Schoonen, Francien Talens, Colin Stok, et al.
NAR Cancer|November 29, 2024
RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft modelsFrancien Talens, Vivian Oliviera Nunes Teixeira, Yannick P Kok, et al.
Nature Communications|November 3, 2022
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signalingDario Zimmerli, Chiara S Brambillasca, Francien Talens, et al.
Pageof 1